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1 INTRODUCTION 
 
1.1 Epidemiology of cancer 
 
 Cancer is considered one of the most dangerous diseases that threaten human health 
and is the second leading cause of death worldwide. Recent statistics reported by the World 
Health Organization (WHO) indicated that cancer was responsible for an estimated 9.6 
million patient deaths in 2018, and this number will increase to 15 million by 2030 [1]. 
Independently of gender and age, Asia accounted for the highest cancer incidence and 
mortality with 43.6% and 49.6%, respectively, followed by Europe with 25.0% and 22.0% 
[2]. Breast cancer is the most prevalent diagnosed cancer among females, corresponding to 
25% of the cases, and the second leading cause of cancer death, while cervical cancer ranks 
fourth for both incidence and mortality among women around the world [3,4]. In Europe it 
was estimated that cancer incidence increased with 3.9 million new cases, and 1.9 million 
deaths reported during 2018. Among different types of cancer, female breast cancer ranked as 
the first and common type of cancer with 523,000 detected cases, followed by colorectal, 
lung, and prostate cancer [5]. Moreover, high cancer burden is characteristic of Central and 
Eastern European countries, including Hungary [6]. 
 In Hungary both breast and cervical cancers are prevalent malignancies in women that 
may lead to deaths [7,8]. Among Hungarian women 74,920 and 18,610 breast and cervical 
cancer deaths have been recorded, respectively, during the period 1979-2013, with mortality 
rates of 12.19 and 10.29 per 100,000 persons per year [9]. 
 In Iraq, according to the latest Iraqi Cancer Registry, breast cancer was the most 
prevalent type among the registered malignant neoplasms affecting the community, 
considered as the first cause of cancer death with a mortality rate of 23.6% among Iraqi 
women during 2016 [10,11].  
Breast cancer is commonly classified into subtypes based on the presence or absence 
of human epidermal growth factor-2 (HER2), estrogen receptors (ER), and progesterone 
receptors (PR). Subtypes positive for these receptors more often respond to adequate 
hormonal therapy [12]. Triple-negative breast cancer (TNBC) on the other hand, globally 
accounting for 15-20% of all diagnosed breast cancers, is one of the most aggressive and 
challenging subtypes representing a malignancy which is treated only with conventional 
chemotherapeutic drugs due to the lack of targets for hormonal therapy [13,14].  
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Human cervical cancer is currently one of the crucial global health problems and a 
leading cause of mortality in women during their reproductive years. A substantial portion of 
the cases is related to human papillomavirus (HPV) infection [15]. Chrysostomou et al. 
(2018) and Goodman (2015) proved that HPV variants 16 and 18 are highly associated with 
carcinogenesis, and HPV-16 and -18 are responsible for approximately 20% and 50% of 
cervical cancer cases, respectively [16,17]. 
 
1.2 Natural products 
 Chemotherapy is one of the best therapeutic strategies to treat cancer disease but 
adverse effects and acquired drug resistance may lead to failure for standard therapy [18]. 
There is still an urgent requirement to develop novel effective, reliable and safe anticancer 
agents for the treatment of a wide range of cancerous disorders [19]. Traditionally, attention 
has been concentrated on the use of natural products and their semi-synthetic derivatives to 
treat human diseases, including cancer [20]. Plants are substantial sources of natural 
compounds which can be used as models for design and synthesis of innovative drugs [21]. 
Hence, in modern therapeutics, more than 50% of medicines prescribed worldwide are based 
on natural products or their derivatives [22].   
 Phytochemicals (plant-derived compounds) play an essential role in drug 
development and discovery. Based on their wide range of bioactivities, low cost, and 
chemical diversity, they are generally considered an essential factor in anticancer drug 
research [23,24]. Structures of natural products are useful scaffolds for chemical 
diversification and this property makes them an optimal source for novel compounds in drug 
discovery [25]. Phytochemicals are regarded as an essential source of anticancer agents that 
have substantial antiangiogenic, antimetastatic, antiproliferative, and proapoptotic effects in 
both animal and cell-based models [14,26]. The discovery of active new derivatives through 
modification of the natural product structure is a promising approach for the development of 
innovative first-in-class anticancer drugs [27]. Actually, over 75% of current anticancer drugs 
introduced between 1981 and 2008 had been discovered either directly from natural products 
or developed based on their semi-synthesis derivatives (e.g. vinblastine, vincristine, 
paclitaxel, camptothecin, and topotecan) [28,29]. Several plant species and their derivatives 
exerted strong antiproliferative and proapoptotic effects in different types of cancer cell lines  
[30–33]. Additionally, the plants which contain high amounts of flavonoids in their structure 
are accepted in traditional medicine as chemotherapeutic and chemopreventive agents in 
some countries [34].  
 
3 
 
1.2.1 Flavonoids 
 
 Polyphenols are considered one of the largest classes of phytochemicals, which are 
classified into two principal categories: non-flavonoids and flavonoids (Fls). Non-flavonoids 
are divided into main subclasses including phenolic acids (cinnamic acid derivatives, benzoic 
acid derivatives) and stilbenoids [35]. On the other hand, based on their chemical structure 
characterized by two (A and B) phenyl rings connected by a heterocyclic C ring and 
depending on the position of the phenyl rings, the functional groups, the arrangement of 
hydroxyl groups and the presence or the absence of unsaturation in the C ring, flavonoids are 
classified into different subgroups which include: flavonols, flavones, flavanones, 
isoflavones, chalcones, and anthocyanidins [36,37].   
 Flavonoids, in particular, are considered the largest class of polyphenolic secondary 
metabolites that are widely distributed in nature and play a prominent role in plant 
physiology. In addition to protecting the plants from different stresses, they also act as 
detoxifying and defensive agents [38]. Despite many controversial views regarding the 
current lack of clinical results, Fls and other phytochemical metabolites continue to have a 
promising value in cancer research. Most of the new clinical studies on plant secondary 
metabolites and their derivatives have been applied towards drug discovery and combating 
cancer [39]. During the last few decades, many studies showed that isolated and synthesized 
Fl analogs exerted different pharmacological activities such as antibacterial, antiviral, anti-
inflammatory, antioxidant, and antitumor effects against a broad range of human cancer cell 
lines [23,40,41]. Fls and their synthetic analogs have appeared as hopeful agents for the 
treatment and prevention of breast cancers [42]. Rodriguez et al. (2018) mentioned that Fls 
isolated from the leaves of Chromolaena tacotana caused excellent antioxidant and 
antiproliferative activity on the breast MDA-MB-231 cancer cells [43]. Additionally, it was 
investigated that treatment with fisetin induces growth inhibition and apoptosis in TNBC 
(MDA-MB-231 and MDA-MB-468) and ER+ (MCF-7) breast cancers [44]. Yao et al. (2012) 
synthesized two flavone analogs and discussed their potent antiproliferative activities in two 
types of breast cancer cells, MDA-MB-231 and MCF-7 [24]. Different kinds of Fls isolated 
from the stems and roots of Crotalaria bracteata showed good cytotoxicity against MCF-7 
cancer cell lines [45]. Six Fls isolated from propolis induced apoptosis, cytotoxic and 
antioxidant effects in both MDA-MB-231 human breast and colon cancer HCT-116 cells 
[46]. 
Moreover, the cytotoxic activity of 42 different Fls on the MCF7-SC human breast 
cancer stem-like cell line described the relationship between Fl structure and its cytotoxicity 
[47]. Furthermore, their cytotoxicity was evaluated against cervical, ovarian, pancreatic, and 
prostate cancer [48,49]. Treatment of HPV16 or HPV18 positive human cervical cancer with 
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dietary Fls, including naringenin, naringin, and hesperetin, can lead to concentration- and 
time-dependent inhibition of cell proliferation through the improvement of apoptosis and the 
induction of cell cycle arrest [50]. Nugraha et al. (2017) showed that Fls derived from 
Eriocaulon cinereum extraction suppressed the growth of HeLa cells with good IC50 value 
[51]. While hesperetin exhibits apoptotic action against SiHa cervical cancer cells [52], the 
anticancer activities of 26 flavanone derivatives on colorectal cancer cells (HCT116) were 
reported to block G1 cell cycle progression and inhibit the clonogenicity of cells [53]. Four 
Fls, namely naringenin, quercetin, chrysin, and vinculin, which were isolated from the 
rhizome of Docynia delavayi, exerted high anti-tumor activity on human cervical 
adenocarcinoma cell (HeLa),  human hematomas cell (HepG2), and esophageal carcinoma 
cell (EC109) [54]. Flavanone isolated from Chromolaena leivensis (Hieron) effectively 
inhibited the cell growth in the breast MDA-MB-231, cervix SiHa, prostate PC3, colon HT-
29, and lung A549 cancer cells, with exhibited cell cycle arrest in lung cells [55]. Liu et al. 
(2015) examined the anticancer efficacy of different types of Fls against various types of 
leukemia cells, including human leukemia (HL-60) cell line, and found that Fl compounds 
exhibited good cytotoxic activity against leukemia [56]. Antioxidation, antiproliferation, 
antiangiogenesis, and apoptosis induction are considered as the main mechanisms behind the 
anticancer effects of Fls [31,57]. Besides, Fl derivatives can cause cancer cell apoptosis 
through a caspase-dependent pathway [58]. Furthermore, they can be affected by free radical 
scavenging activity [59] or protection of the tissues from damage caused by Reactive Oxygen 
Species (ROS) through the block formation of ROS [60]. Several studies have reported that 
Fls are essential natural antioxidants, which are mostly associated with the treatment of 
various diseases and disorders, including cancer, and also, some Fls can behave as both 
anticancer agents and antioxidants [61,62].  
 
1.2.1.1 Naringenin 
 
 Naringenin (NG), which belongs to the flavanone subclass, is considered as one of the 
greatest abundant dietary Fls predominantly present in grape, citrus fruits, and tomato. It 
displays several beneficial pharmacological activities on human health, including 
cardioprotective, anti-inflammatory, antiviral, antioxidant, and anticarcinogenic effects 
[63,64]. Rebello et al. (2020) proved the safety of naringenin in healthy adult humans after 
the consumption of a single oral dose up to 900 mg  [65]. 
Recently, several in vivo and in vitro studies demonstrated that NG could effectively 
inhibit cell proliferation and migration, induced apoptosis, and suppressed cell cycle in 
several types of human cancer cells, including hepatocellular carcinoma, prostate, pancreas, 
colon, bladder, cervical, uterine, breast cancer and leukemia [36,66–73]. In an in vivo 
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experimental study Sabarinathan et al. (2011) found that, NG has potent antioxidant and 
antiproliferative effects against cerebrally implanted glioma cells in rats [74]. Besides, NG 
was shown to exhibit anti-oxidant effects and to alleviate cerebral edema in cases of 
ischaemic stroke [75]. Also, Arul et al. (2013) reported in vitro that NG had antiproliferative 
and apoptotic effects on the human hepatocellular carcinoma (HepG2) cell lines through 
induction of the cell cycle arrest and activation of caspase-3 [76].  Naringenin exhibited 
cytotoxic effects in the MDA-MB-231 cells characterized by growth inhibition, cell cycle 
was arrested in the sub G, G1, and G2 phases besides the apoptotic effects represented by the 
elevation of both caspase-3 and caspase-9 activities [77,78]. However, the anticancer activity 
of NG is not strong enough to apply clinically. The use of natural NG as a cancer 
chemotherapeutic or chemopreventive agent requires the development of NG derivatives that 
can prompt cytotoxicity at low concentrations [79]. Therefore, based on the chemical 
structure of NG, several research groups have made attempts to design and synthesize new 
NG derivatives to improve their biological properties [66,71,80,81]. A lot of NG derivatives 
were synthesized by the modification of phenolic groups by alkylation and esterification to 
produce new molecules with potent cytotoxic effects against human colon cancer cells [71]. 
Lee et al. (2003) conducted an in vivo study to evaluate the anti-atherogenic effects of 
naringenin semi-synthetic modifications in high-cholesterol fed rabbits [82]. Recently it has 
been indicated that 4ʹ- and 7-O-methylated naringenin derivative decreased the epileptic 
seizures in mouse and zebrafish models [83]. 
On the other hand, the modification of naringenin at the keto group also provided interesting 
pharmacological compounds like thiosemicarbazone derivatives, which displayed significant 
DNA binding properties and antioxidative impacts [84]. Liu et al. (2017) produced NG 
derivatives with a tertiary amino side chain that enhanced the antiproliferative activities of 
NG against four different human cancer cells: lung (A549), breast (MCF-7), colon 
(HCT116), and cervical (HeLa) [66]. Besides, the triacetyl derivative of flavanone recorded a 
high induction of antiproliferative and degradation activity of DNA in MCF-7 cancer cells 
[85]. Furthermore, Zaim et al. (2018) found that the synthesized naringenin-cyclic-
aminoethyl derivatives were potent cytotoxic agents and caused mitochondrial apoptosis in 
the human breast and cervix cancer [86]. 
 Oximes are essential compounds used as chemical building blocks for the synthesis of 
pharmaceuticals and agrochemicals [87]. Oximes and oxime ethers are important 
intermediates that have medium to excellent cytotoxicity against cancer cells [88]. The oxime 
functional group quickly bonds with relevant organic groups such as cyano, nitro, amino, and 
carbonyl groups that can serve as a convenient protective group [89]. Turkkan et al. (2012) 
and Potaniac et al. (2014) synthesized and characterized the naringenin E-oxime (NGOX) 
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derivative and noted that antioxidant and scavenging reactive oxygen species (ROS) activity 
was significantly higher than NG itself [90,91]. Recently, Kocyigit et al. (2016) investigated 
that both NG and its oxime analogs have good antioxidants with protecting cell activity 
against oxidative damage induced by hydrogen peroxide [92]. 
Furthermore, in vivo, NGOX relieved the side effects (nephrotoxicity, hepatotoxicity, and 
genotoxicity) induced in rats after treatment with cisplatin [93]. On the other hand, as 
compared to their respective parent compounds, the modification of NGOX derivatives was 
observed to improve significantly in cytotoxicity against different types of cancer cells, and 
they are considered promising leads for the development of cytotoxic agents [94–97]. 
However, even though numerous attempts to synthesize and evaluate the pharmacological 
activity of NGOX have been described in several articles [90–92], only a limited number of 
oxime ether derivatives have been studied in the literature [98]. 
  
1.2.1.2  Protoflavones 
 
 Protoflavones (PrFl) represent a rare particular class of natural Fls with an unusual 
non-aromatic B-ring. Such compounds most typically occur in fern species (e.g., Thelypteris 
and Pseudophegopterys sp.) [99]. Several studies mentioned the isolation and/or semi-
synthetic preparation of new natural PrFl, recording promising bioactivity against different 
cancer cells both in vitro and in vivo [100–103]. Hunyadi et al. (2011) developed a one-step 
semisynthetic method to prepare protoapigenone (for chemical structure, see Fig. 1, blue 
fragment of compound 9) directly from its 4ʹ-hydroxyflavone analog, apigenin, and showed 
that a 1ʹ-O-alkyl substituent may increase cytotoxic activity on some human cancer cell lines 
[104]. The treatment with PrFl derivatives significantly suppressed viability and growth of 
human breast (MDA-MB-231 and MCF-7), lung (A549), liver (HepG2, and Hep3B), ovarian 
(MDAH-2774 and SKOV3), colon (HT-29), pancreas (PANC-1) and cervical (HeLa) cancer 
cell lines, with low and in some cases sub-micromolar IC50 values [99,105–108]. PrFls were 
demonstrated to trigger apoptosis by activating caspase-3 and increase the apoptotic subG1 
cell population, besides suppressing the S, G2/M phase in the treated cancer cells [106,109]. 
Further, Wang et al. (2012) demonstrated that protoapigenone inhibited the ataxia-
telangiectasia and Rad3-related protein (ATR)-mediated activation of checkpoint kinase-1 
(Chk-1), which is a critical component of replication-associated DNA damage response 
(DDR) [102]. Along with the ataxia-telangiectasia mutated kinase (ATM), this pathway is an 
attractive novel antitumor target with several related ongoing clinical trials [110–112]. 
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2 SPECIFIC AIMS OF THE STUDY 
 
The present PhD work aimed to study the antitumor potential of a set of new 
flavonoid derivatives, some (naringenin oxime derivatives) to be prepared and 
characterized within the scope of this work, and others (protoflavone-chalchone hybrid 
compounds) prepared and characterized by collaborators. Gynecological (cervical and 
breast) cancer cell lines were selected to evaluate the compounds’ in vitro antitumor 
activity, and we also aimed to evaluate possible mechanism of action for selected 
compounds. The specific aims were the following. 
 
 Design and synthesis of naringenin oxime and oxime ether derivatives. A 
straightforward chemical strategy was chosen to prepare nitrogen-containing 
flavonoid analogs, and we also aimed to possibly isolate by-products of the reactions 
when performing the preparative chromatographic purification of the compounds. 
 Determination of the in vitro antiproliferative activity of the synthesized naringenin 
oxime derivatives on human gynecological cancer cell lines.
 Investigation of the possible mechanism of action of the most active naringenin 
derivatives through the antioxidant and proapoptotic properties by determining cell 
cycle analysis and caspase-3 activity.
 Examination of the antioxidant activity of the synthesized naringenin oxime 
derivatives based on their efficiency to scavenge diphenyl-2-picrylhydrazyl, oxygen 
radical absorbance capacity and xanthine oxidase inhibitory assays.
 Evaluation of the antiproliferative activity of protoflavone-chalcone hybrid 
compounds on gynecological cell lines.
 Evaluation of the cell cycle and caspase-3 activity of gynecological cells upon 
treatment with protoflavone derivatives. This work was aimed as participation in an 
international collaboration study on the possible mechanism of action of these 
compounds.  
 Evaluation of the pharmacological benefit of coupling protoflavones and chalcones 
into hybrid compounds, by performing experimental and virtual combination studies 
on their relevant fragments. 
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3 MATERIALS AND METHODS 
3.1 Chemicals 
 
3.1.1 Synthesis of naringenin oximes and oxime ether derivatives 
  Naringenin (purity: 98%), used as a starting material, was purchased from Indofine 
Chemical Company Inc. (Hillsborough, NJ, USA). Ethanol 96% was obtained from Molar 
Chemicals Ltd. (Halásztelek, Hungary). All other reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Normal phase thin-layer chromatography (TLC) (Silica gel 
60F254, E. Merck, Darmstadt, Germany) was used to monitor the reaction progress. 
Purification was carried out by flash chromatography on a CombiFlash Rf+ Lumen 
Instrument (Teledyne Isco, Lincoln, NE, USA) with integrated UV-Vis, photodiode-array 
(PDA) and evaporative light-scattering (ELS) detection, and using commercially available 
pre-filled columns (Teledyne Isco, Lincoln, NE, USA) for normal-phase separations in a 
detection range of 210–366 nm. Naringenin oximes and oxime ethers were characterized by 
using NMR and MS. 1H (500.1 MHz) and 13C (125.6 MHz) NMR spectra and recorded on a 
Bruker Avance DRX-500 spectrometer (Bruker, Billerica, MA, USA). 
 Naringenin oximes and oxime ethers derivatives (1-8) were synthesized and 
characterized as published before [90]. Briefly, naringenin (1.00 g) was dissolved in 100 mL 
of EtOH, then 3 equiv. (0.77 g) of hydroxylamine hydrochloride and 3-equiv (0.62 g) of 
KOH were added. The reaction mixture was refluxed for 48 h, and then the solvent was 
evaporated under vacuum. The residue was re-dissolved in water (100 mL) and the aqueous 
phase was extracted with EtOAc (3 × 100 mL). The organic phase was combined, dried over 
Na2SO4, and evaporated to dryness. Compounds were purified by flash chromatography on 
silica with a solvent system of n-hexane—EtOAc—formic acid (15:4:0.25, v/v/v). 
 Naringenin oxime ethers were synthesized as follows. An aliquot of 100 mg of 
naringenin was dissolved in 15 mL of pyridine, then three-equivalents of the corresponding 
alkyl or aryloxyhydroxylamine hydrochloride was added, and the mixture was refluxed for 
48–96 h. Completion of the reaction was decided based on continuous TLC monitoring. 
When starting material was not detectable any more, the solvent was evaporated under 
vacuum. After that, 50 mL of water was added to the residue, and solvent-solvent extraction 
was performed with EtOAc (3 × 50 mL). Then the combined organic phase was dried over 
Na2SO4, filtered, and evaporated to dryness. Each crude mixture was purified with flash 
chromatography on polyamide with a solvent system of CH2Cl2–MeOH (9.9:0.1, v/v). 
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3.1.2 Protoflavone derivatives obtained from collaborators   
 Using protoapigenone 1′-O-propargyl ether (9) [99], four new hybrid compounds 
(10a-d) were prepared at the Institute of Chemistry (University of Eötvös Loránd, Budapest, 
Hungary) and the Institute of Pharmacognosy, University of Szeged, Szeged, Hungary. Each 
of these compounds joined two fragments, a protoflavone and a chalchone or ferrocene (11a-
d) through a triazol function (Figure 1). 
 
Figure 1. Chemical structure of protoapigenone 1′-O-propargyl ether (9) and the 
protoflavone-chalcone hybrids with triazole linkers (10a-d). The hydroxymethyl derivatives 
(11a-d) corresponding to the chalchone fragment were also tested as reference compounds 
for the hybrids. 
 
3.2 Cell lines and culture conditions 
 A panel of human gynecological cancer cell lines, including human breast carcinoma 
(MCF-7) as a model for ER+, human breast adenocarcinoma (MDA-MB-231) as a model for 
TNBC, cervical HPV 18+ adenocarcinoma (HeLa) and HPV 16+ squamous cell carcinoma 
(SiHa), with additional human leukemia cells HL-60 and non-cancerous mouse embryonic 
fibroblast cell line (NIH/3T3) were used as in vitro design to study the antitumor activity of 
the tested compounds. The SiHa and human leukemia HL-60 cells were obtained from the 
American Tissue Culture Collection (ATCC), Manassas, VA, USA, while all the other cell 
lines were from the European Collection of Cell Cultures (ECCAC), Salisbury, UK. 
According to the distributors’ instructions, all human gynecological cancer cell lines and non-
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cancerous mouse embryonic fibroblast cell line (NIH/3T3) were cultivated in flasks of 75 
cm2 in minimal essential medium (MEM) and enhanced with 10% heat-inactivated fetal 
bovine serum (FBS), 1% antibacterial-antimycotic solution (penicillin-streptomycin-
amphotericin B) and 1% non-essential amino acids.  
HL-60 leukemia cells were cultivated in RPMI 1640 medium containing 10% FBS, 1% 
antibacterial-antimycotic mixture and 1% L-glutamine, and incubated in a humidified 
atmosphere at 37°C enclosed with 5% carbon dioxide (CO2). The density of the cells for each 
experiment was measured with a Luna Automatic Cell Counter (Seoul, South Korea) using 
trypan blue solution. All chemicals and media that were used in our research, if not specified 
otherwise, were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary) and Lonza Group 
Ltd. (Basel, Switzerland), respectively [100,101]. 
 
3.3 Treatment with the compounds   
 The synthesized compounds were solubilized in dimethyl sulfoxide (DMSO) as a 50 
and 10 mM standard solution for naringenin oxime and protoflavone derivatives, 
respectively, and stored at –20°C with minimal exposure to light to avoid oxidation. The 
stock solution was immediately diluted with a culture medium before each treatment to reach 
the final concentrations for the different experiments. Two concentrations (25 and 50 µM) 
were selected for screening the bioactivity of initial naringenin oxime derivatives on breast, 
cervical and HL-60 cancer cell lines, and the values of half-maximal inhibitory concentration 
(IC50) were estimated only for those compounds that elicited antiproliferative activity with 
more than 75% growth inhibition at 50 µM, by repeating adjusted dilutions (1–50 µM) of the 
potent compound. On the other hand, the gynecological cells were exposed to ten different 
concentrations of each compound of protoflavone derivatives (0.039, 0.07, 0.1, 0.31, 0.62, 
1.25, 2.5, 5, 10 and 20 µM). Cisplatin was used as a positive control (0.1, 0.3, 0.6, 1.25, 2.5, 
5, 10, and 20 µM), while the negative control included the cells that were treated only with 
MEM.   
 HL-60 cells were seeded at 1×104 cells per well and directly treated on the same day, 
whereas the gynecological and NIH/3T3 cells were seeded at 5×103 cells per well, and 
overnight pre-incubation was done to permit the adhesion of the cells to the bottom of the 
well before the treatment (I, II). 
11 
 
3.4 Antiproliferative activity 
 The colourimetric )[3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide](  
MTT assay was employed to estimate the ability of the prepared compounds to suppress the 
proliferation of human gynecological (MDA-MB-231, MCF-7, HeLa and SiHa), human 
leukemia (HL-60) cells and non-cancerous mouse embryonic fibroblast (NIH/3T3) cell lines 
as previously characterized [102,103]. Briefly, the cells were seeded and treated in 96-well 
microplates with the final volume per well kept at 200µL and incubated for 72 hours in the 
same condition at 37°C in a humidified atmosphere of 5% CO2. After incubation, 44 µL of 
MTT solution (5 mg/mL of PBS) was added to each well, and incubation continued for 
another four hours. Subsequently, the supernatant was removed carefully and the precipitated 
purple formazan crystals were solubilized by adding 100 μL/well of DMSO and gently 
shaking them for 1h at 37°C (Stat Fax-2200, Awareness Technology INC, USA). Absorbance 
was measured at a wavelength of 545 nm using an automatic microplate reader (Stat Fax-
2100; Awareness Technology INC, USA). In the case of leukemia cells, the precipitated 
crystals were dissolved in 10% sodium dodecyl sulfate (SDS) with acid HCl 0.01 mM and 
incubated for 24 h, the absorbance read at 545 and 630 nm.  
 
3.5 Cell cycle analysis 
 The cell cycle distribution was characterized by flow cytometry, as described by 
Sinka et al. [104], and the cellular DNA content was detected by staining with propidium 
iodide (PI). Briefly, adherent cancer cells were seeded in six-well plates at a density of 4×105 
cells per well and allowed to grow for 24 h. On the second day, cells were treated with the 
testing compounds in two concentrations related to their IC50, with an incubation period of 24 
hours. Subsequently, cells were harvested with trypsin (250 µL/well), washed with PBS, re-
suspended, and fixed with 70% cold ethanol, which was added dropwise to the cell pellet and 
maintained at -20°C until further analysis. Directly before the analysis, the fixed cells were 
washed with cold PBS, stained with a 300 µL of dye solution containing 0.1 mg/mL of PI in 
the presence of 0.02 mg/mL of RNAse, 0.003 mL/mL of Triton-X-100 and 1.0 mg/mL of 
sodium citrate in distilled water. Then they were incubated in the dark at room temperature 
for an hour. Finally, 700µL of PBS was added to detect the DNA contents by flow cytometry 
(Partec CyFlow, Partec GmbH, Munster, Germany). For each experiment, at least 20,000 
events per sample were calculated. Also, the measured data and the distribution of the cells in 
the different cell cycle phases (subG1, G0/G1, S, and G2/M) were expressed as DNA 
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histograms by using ModFit LT 3.3.11 software (Verity Software House, Topsham, ME, 
USA).  
 
3.6 Determination of caspase-3 activity 
 Caspase-3 colourimetric assay kit, purchased from Sigma-Aldrich, Saint Louis, MO, 
USA., was used to determine the cysteine-aspartic proteases-3 (Caspase-3) in conformity to 
the manufacturer’s instructions and according to the procedure which had been published 
before [105]. Briefly, cells were seeded at a density of 12×106 cells in tissue culture flasks 
and allowed to grow and attach overnight. The adhered cells were treated with appropriate 
concentrations of the prepared compound and incubated for 24 or 48 h. Subsequently, the 
cells were scraped, harvested, centrifugated, and washed with PBS. They were re-suspended 
and incubated in lysis buffer on ice for 20 min, and the supernatant was used after the cold 
centrifugation of the lysates. Assays were performed in a 96-well plate with collected 
supernatant by incubating 5 µL of cell lysates with 10 µL of selective caspase-3 substrate in a 
final volume of 100μL of assay buffer, then incubated at 37°C in the dark for 24 h. Finally, 
the absorbance was measured at 405 nm with a microplate reader (Stat Fax 2100, Awareness 
Technology INC, USA). The changes in caspase-3 activity were determined after comparing 
the absorbance of the treated samples with the untreated controls.  
 
3.7 Antioxidant activity   
3.7.1 Diphenyl-2-picrylhydrazyl (DPPH) assay 
 The in vitro antioxidant activity of the NGOX derivatives was evaluated based on 
their efficiency to scavenge stable DPPH according to the method presented by  Fukumoto 
and Mazza (2000) [106] with some modifications. 1,1ʹ-Diphenyl-2-picrylhydrazyl (DPPH) 
was purchased from Sigma-Aldrich Hungary. The measurement was carried out on a 96-well 
microplate. Series microdilution of samples (starting with 150µL)  was prepared from the 
stock solution (10 mM). To each well, 50 µL of DPPH reagent (100 µM in HPLC grade 
MeOH) was added to gain 200 µL working volume. The microplate was stored in the dark at 
room temperature for 30 min. Sample absorbance was measured at 550 nm by using a 
FluoStar Optima plate reader (software version 2.20R2, BMG Labtech Ortenberg, Germany). 
The percentage of free radical scavenging activity of the different samples was calculated by 
the following equation: Inhibition (%) = (A0 - As)/A0 × 100, and EC50 values were 
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calculated by Graph Pad Prism 6.05 software. Rutin (0.01 mg/mL in HPLC grade MeOH) 
was used as a reference standard and DMSO was used as a blank control. 
 
3.7.2 Oxygen radical absorbance capacity (ORAC) assay 
 The ORAC assay was performed according to the method of Mielnik et al. (2011)  
[107]. Briefly, 20 µL of extracts (stock solution concentration of 0.002 mM) were mixed with 
60 µL of AAPH (12 mM final concentration) and 120 µL of fluorescein solution (70 nM final 
concentration), then the fluorescence was measured through 3 h with 1.5-min cycle intervals 
with a BMG Labtech FluoStar Optima plate-reader. All experiments were carried out in 
triplicate, and trolox was used as a standard. The antioxidant capacity was expressed as µM 
Trolox Equivalent per µM of pure compound (µM TE/µM), as calculated by Graph Pad 
Prism 6.05. 
 
3.7.3 Xanthine-oxidase inhibitory assay 
 To assess xanthine-oxidase (XO) inhibitory activity, a continuous spectrophotometric 
rate determination was used, based on a modified protocol of Sigma. The absorbance of XO-
induced uric acid production from xanthine was measured at 290 nm for 3 min in a 96-well 
plate on a BMG Labtech FluoStar Optima plate-reader. The XO-inhibitory effect was 
determined via the decreased production of uric acid. The samples (10 mM stock solution) 
were prepared in DMSO. For enzyme-activity control, the final reaction mixture comprised 
100 µL of xanthine solution (0.15 mM, pH = 7.5), 150 µL of buffer (potassium phosphate 
with 1 M KOH, pH = 7.5) and 50 µL of XO (0.2 units/mL) in a 300 µL well. The reaction 
mixture for inhibition was made with 100 µL of xanthine, 140 µL of buffer, 10 µL of sample 
and 50 µL of XO. Allopurinol was used as positive control. Test compound samples were 
added in appropriate volumes so that the final concentration of DMSO in the assay did not 
exceed 3.3% of the total volume. All experiments were conducted in triplicates. The reaction 
was initiated by the automatic addition of 50 µL of XO solution to a final concentration of 
0.006 units/mL. The inhibitory percentage values were calculated by using Graph Pad Prism 
6.05 software. 
 
3.8 Combination study of relevant fragments vs hybrids 10b-d  
 Two combination studies were performed: a virtual and an experimental one. In the 
case of the virtual study, cell viability data obtained following treatment with the hybrid 
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compounds 3b-d were analyzed in comparison with data obtained for their corresponding 
relevant fragments, such as compounds 1 and 8b-d, and the hybrid compounds were 
considered as 1:1 ratio mixtures of compound 1 and the corresponding fragment. Two 
separate experiments were performed, each in triplicate. In the case of the experimental 
combination study, cell viability data obtained for equimolar mixtures of the above-
mentioned fragments were tested in comparison with the corresponding single-treatment 
controls. In this bioassay, two separate experiments were performed, each in duplicate.  
Calculations were performed using CompuSyn software. In each case, raw cell viability data 
from all replicates were averaged, and the resulting single dataset was analyzed as suggested 
by Chou [108]. CI values obtained this way were then used to mathematically describe the 
extent of pharmacological benefit gained by the coupling (virtual combination) in comparison 
with a combined effect of the mixture of fragments (experimental combination). “Synergism” 
in the virtual combination means that the hybrid exerts significantly stronger cytotoxicity 
than just a sum of that of its fragments. 
 
3.9 Other bioassays performed in collaboration  
 Cell death analysis by AV/PI labelling, and studies on the effect of compounds 10a-d 
on the intracellular ROS/RNS levels, and on the depolarization of the mitochondrial 
membrane [109] were performed in cooperation with the group of Dr. Milica Pešić, Institute 
for Biological Research, Department of Neurobiology, University of Belgrade, Belgrade, 
Serbia.  
  DNA damage response studies were performed in cooperation with the group of Prof. 
Hui-Chun Wang, Graduate Institute of Natural Products, Kaohsiung Medical University, 
Kaohsiung, Taiwan. The effect of compounds 10a-d on the ATR-dependent phosphorylation 
of checkpoint kinase-1 (Chk1) was evaluated on MCF-7 breast cancer cells by Western 
immunoblotting, as published before [110]. For more details see Ref.  (I). 
 
3.10   Statistical analysis  
 
 Data were collected from two separate experiments in triplicates for antiproliferative 
activity of protoflavone derivatives and cell cycle analysis or five replications for 
antiproliferative activity of naringenin oxime compounds and caspase-3 activity at each 
tested concentration; and evaluated by Graph Pad Prism 5.01 (Graph Pad Software, San 
Diego, CA, USA) using one-way ANOVA followed by Dunnett’s post-hoc test for 
15 
 
comparison of multiple results. IC50 values were calculated by (log inhibitor vs normalized 
response) nonlinear regression model. The results were expressed as means ± standard error 
of the mean. The results were considered statically significant at *, ** and ***,   p < 0.05, p < 
0.01 and p < 0.001, respectively. 
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4 RESULTS 
 
4.1 Naringenin oxime derivatives 
 As part of my own contribution to this work, naringenin oxime and oxime ethers were 
prepared. Two geometric isomers of naringenine oxime (2 and 3) were obtained from 
naringenin (NG; 1) by reacting it with hydroxylamine hydrochloride in ethanol in the 
presence of potassium hydroxide, and purifying the products by column chromatography. 
After characterization by HRMS and 1H-, and 13C-NMR, compound 2 was identified as the E 
isomer, while compound 3 as the minor Z isomer, which was prepared by us for the first time. 
Five oxime ether derivatives (4–8) were also prepared by a similar one-step synthesis from 
the reaction of NG (1) with ethoxy-, methoxy-, allyloxy-, t-butoxy-, or benzyloxyamine 
hydrochloride, respectively, in the presence of pyridine. In these reactions, the exclusive 
formation of the E isomers was observed. After purification by using flash chromatography, 
the chemical structures of the prepared compounds were identified by NMR and HRMS 
techniques, and they are shown in Figure 2. 
 
Figure 2. Chemical structures of naringenin (1) and its oxime (2 and 3), and oxime ether 
derivatives (4-8). 
 
4.2 Pharmacological activities of naringenin oxime derivatives 
4.2.1 Antiproliferative activity of naringenin oxime derivatives 
 The in vitro antiproliferative activity of NG (1) and its oximes (2, 3) and oxime ethers 
(4-8) were evaluated against four human adherent gynecological cancer cell lines, such as 
SiHa and HeLa (cervical), and MDA-MB-231 and MCF-7 (breast), and also against a human 
leukemia (HL-60) cell line. Cisplatin, a chemotherapeutic drug was used as a positive control. 
After the initial bioactivity screening by using MTT assay with two concentrations of 25 and 
50 μM, IC50 values were determined only for those compounds that exhibited 
antiproliferative activity with an over 75% growth inhibition at 50 μM (Table 1). We found 
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that among all the applied compounds, the t-butyl substituted naringenin oxime ether (6) 
exerted significant and dose-dependent antiproliferative activity against all tested cancer cell 
lines. 
In contrast, we found that naringenin (1) and Z-oxime (3) caused limited  growth-inhibiting  
activity in the treated cancer cell lines. On the other hand, the E oxime (2) and the allyl-
derivative (7) showed a limited growth inhibition in the MCF-7 and HeLa cancer cell lines at 
the higher concentration. Also, the methyl derivative (4) and benzyl-derivative (8) exerted 
conservative growth inhibition in MCF-7 and HL-60 cancer cell lines, respectively. Based on 
our results, we show for the first time that the E-oxime ethers are stronger antiproliferative 
agents as compared with naringenin and naringenin oximes, mainly if the ether is a bulky 
alkyl group as in the t-butyl derivative 6. Further, we noted that compounds 1-8 did not 
demonstrate a marked cell line selectivity, but MCF-7 and HeLa cells seemed altogether 
more sensitive than MDA-MB-231 and SiHa cells (II). 
 
Table 1. Antiproliferative activities of naringenin (1) and its oxime derivatives (2-8) against 
human gynecological cancer and leukemia cell lines. Cisplatin was used as a positive control; 
SEM: standard error of the mean; n = 5. 
 
 
 
18 
 
4.2.2 Cell cycle distribution affected by naringenin oxime derivatives 
 Among the prepared NGOX derivatives, compound 6 showed the most promising 
antiproliferative effects against gynecological cancer cells and was therefore selected for 
further in vitro studies, including flow cytometric cell cycle analyses, to distinguish the 
mechanism of action. Adherent cancer cells were exposed to compound 6 for 24 h at two 
concentrations in proportion to its IC50 and it is half IC50 -values, i.e., 18 or 36 µM for SiHa, 
12 or 24 μM for HeLa, 15 or 30 µM for MDA-MB-231, and 10 or 20 µM for MCF-7 (Figure 
3A). From the DNA content histogram, we demonstrated that the percentage of the 
hypodiploid (subG1) phase increased significantly in cervical SiHa and HeLa cancer cells, 
which is considered as apoptotic in these cell lines. Also, it was found that compound 6 
caused a significant reduction in the percentage of the G1 phase with a consistent increase in 
the S phase of HeLa cells. SiHa cells showed different responses, which was characterized by 
a significant rise in the proportion of the G1 stage accompanied by a considerable decrease in 
the fraction S phase, which may be a consequence of the blockade of the G1–S transition of 
the cell cycle. However, in the MCF-7 cancer cells, the percentage of  G1 and G2/M phase 
increased, whereas the proportion of S level decreased significantly. These data suggest that 
treatment with compound 6 induced G1 and G2/M phase cell cycle suppression in a 
concentration-dependent manner. On the other hand, no substantial action in TNBC was 
observed with either concentration after treatment for 24 h. Our results of cell cycle analysis 
revealed that compound 6 induced disturbance in the cell cycle distribution followed by cell 
death due to the apoptotic process in HeLa and SiHa cancer cell lines (II) 
 
4.2.3 Caspase-3 activity affected by naringenin oxime derivatives 
 To verify the apoptotic activity of the t-butyl derivative (6), the activity of caspase-3, 
which plays a principal role in various apoptotic responses, has been additionally determined. 
HeLa cells were treated with two different concentrations representing the IC50 and its half 
value (12 and 24 μM) of compound 6 and were incubated for 24 h. The obtained results, 
summarized as fold activity shown in (Figure 3B), revealed that both used concentrations of 
the tested compound produced a considerable increase in caspase-3 activity in a 
concentration-dependent manner, with a rise in the number of measured apoptotic cells 
compared to the number of untreated control groups. Herein, for the first time, we asserted 
that apoptosis was induced in cervical Hela cell lines after handling with naringenin t-butyl 
oxime compound (II). 
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Figure 3. (A) Cell cycle distributions of human gynecological cancer cells after treatment 
with naringenin t-butyl oxime (6). (B) Effect of naringenin t-butyl oxime (6) on the caspase-3 
activity of HeLa cells. Results from 5 replicates are represented as means ± SEM. *, ** and 
*** indicate p < 0.05, p < 0.01 and p < 0.001, respectively, by means of one-way ANOVA 
followed by Dunnett’s post-hoc test. 
 
4.2.4 Antioxidant activity of naringenin oxime derivatives 
  NG (1) and its oxime derivatives (2–8) were evaluated for their possible antioxidant 
activity by testing their ability to scavenge DPPH, and determining their ORAC value and 
XO inhibitory activity. The antioxidant results of its effects were clarified in (Table 2). 
Except for compound (4), all compounds exerted a weak activity in these bioassays when 
compared with the reference standard rutin (for direct scavenging activity) or allopurinol (for 
A
B
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XO inhibition). Surprisingly, the oxime methyl ether derivative (4) exhibited the most potent 
antioxidant activity in both the ORAC and DPPH assays, and this compound (4) was also the 
only one whose activity in the ORAC assay exceeded that of the positive control rutin. The 
E-Oxime (2) was much more active DPPH scavenger than NG (1), while the Z-Oxime (3) 
was an order of magnitude weaker than the E-oxime (2) in this regard. However, regardless 
of the oxime orientation, the ORAC activity of both compounds 2 and 3 was diminished as 
compared to NG (1). None of the compounds exerted a significant XO inhibitory activity at 
as high as 330 µM (II). 
 
Table 2. Antioxidant activity XO inh, DPPH, and ORAC of naringenin (1), and its oxime 
derivatives (2–8). TE: Trolox equivalent; n.d.: not determined. 
 
a Compounds eliciting DPPH scavenging activity less than 50% at the highest applied concentration 
were considered inactive, and the numerical results are not presented; b inhibition % at 330 µM 
 
 
4.3 Pharmacological activities of protoflavone derivatives 
4.3.1 Antiproliferative activity of protoflavone derivatives 
 The cytotoxic activity of relevant fragments (9 and 11a-d) and their newly 
synthesized hybrids (10a-d) were evaluated against human breast carcinoma cell lines MCF-
7 and MDA-MB-231. Additionally, the cytotoxic effects of the target compounds were also 
estimated on HPV 16+ cervical squamous cell carcinoma (SiHa) and HPV 18+ human 
adenocarcinoma epithelial cervical carcinoma (HeLa) in comparison to non-cancerous mouse 
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embryonic fibroblast (NIH/3T3) cell lines. The antiproliferative activity was investigated 
after handling the cells with varying concentrations of each compound ranging between 30 
nM and 20 µM for 72 h and using cisplatin, a conventional chemotherapeutic as a positive 
control group. The results are summarized as IC50 values and 95% in 𝜇M C.I. (Confidence 
Interval) in Table 3. All hybrid compounds displayed potent cytotoxic activity stronger than 
that of the positive control cisplatin, with considerable IC50 values limiting from 0.1 to 3.2 
µM against all the investigated cancer cell lines. The results demonstrated that hybrid 
compounds (10a-d) of PrFl derivatives showed pronounced cytotoxicity compared to their 
fragment (9 and 11b-d) in a dose-dependent manner. Mainly, among these compounds, 
hybrids 10b and 10c exhibited an excellent antiproliferative activity on the examined cancer 
cell lines. In general, TNBC and cervical SiHa cells manifested exceptional susceptibility to 
exposure to hybrid compounds when compared to HeLa and MCF-7. 
Moreover, fragment 11a at all concentrations did not display any cytotoxic effects against all 
cancer cell lines. The most potent cytotoxic compounds 10b and 10c were also tested on non-
cancerous mouse embryonic fibroblast 3T3, and their IC50 values were 0.99 and 0.89 µM 
respectively, demonstrating 3-4 times higher selectivity as compared to their effect on MDA-
MB-231 cells. Furthermore, compounds 9 and 11b-d themselves also exerted significant 
cytotoxic activity (I). 
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Table 3. Antiproliferative activity of hybrid compounds (10a-d), and their corresponding 
fragments (9 and 11a-d) on human gynecological cancer cell lines. C.I.: 95% confidence 
interval, n = 6 from two biological replicates (n = 3 each). Positive control: cisplatin, n = 10 
from two biological replicates (n = 5 each). 
 
(a) 11a exerted below 10% inhibition on each cell line at the highest tested concentration; therefore, it 
is considered as inactive. b Experimental data are available up to 20 µM, IC50 value extrapolated from 
nonlinear curve fitting (log inhibitor vs normalized response model) by GraphPad Prism 5.0. 
 
4.3.2 Cell cycle distribution affected by protoflavone derivatives 
 Flow cytometric examination was applied to investigate the cytotoxic mechanism of 
selected potent antiproliferative compounds 10b and 10c  and to check their ability to induce 
alteration in the cell cycle progression and apoptosis induction towards SiHa and MDA-MB-
231 cell lines. Cell cycle distributions were determined after the treatment of both cells with 
doses corresponding to IC50 and its double concentrations for 24 h. The effects of the 
prepared compound on the cell cycle are explained in Figure 4. The flow cytometric assay, 
when compared with the control groups, showed that both cancer cell lines exhibited an 
increase in the proportion of apoptotic cells after treatment with compound 10b and 10c in a 
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dose-dependent manner. It indicated that both compounds in both cancer cell lines caused a 
substantial increase in the hypodiploid (sub-G1) proportions stage, and this influence was 
accompanied by a considerable decrease of the G1 step in MDA-MB-231 cells, while this 
decrease in the G1 of SiHa cells was insignificant. 
Moreover, compound 10c displayed potent effects in both tested cells. Together these data 
suggested that compound 10c efficiently induced apoptosis in TNBC cells. Additionally, as 
noted with increased concentrations of both compounds in MDA-MB-231 and SiHa cells, it 
did not produce any substantial change in the proportion of cells in the S and G2/M aspects 
(I). 
 
Figure 4. Effect of compounds (10b and 10c ) on the cell cycle distribution. (A) MDA-MB-
231 and (B) SiHa cells. Cells treated for 24h; *, ** and ***: p < 0.05, p < 0.01 and p < 0.001, 
respectively, by means of one-way ANOVA followed by Dunnett’s post-hoc test. 
 
4.3.3 Caspase-3 activity affected by protoflavone derivatives 
 To investigate the apoptotic mechanism that is consistent with the cytotoxic property 
and cell cycle distribution of selected compound 10c towards TNBC, caspase-3 enzymes, 
which play an essential role in the apoptotic responses, were used to discover if the cells were 
dying because of necrosis or apoptosis processes. The caspase-3 activity was analyzed in the 
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MDA-MB-231 cancer cells after exposure to compound 10c with 0.2 and 0.4 µM (IC50 and 
double corresponding concentration) and incubated for 24 h. The process showed that 
compound 10c caused a significant increase (2-fold) in caspase-3 activity at a higher used 
level, while the lower concentration did not produce a significant increase in caspase-3 
action, and apoptosis was induced in a concentration-dependent manner. Moreover, after 
increasing the concentration to 0.4 and 1.0 µM and the incubation period to 48 h, the 
compound produced a noticeable, significant elevation in the caspase-3 activity in both tested 
concentrations with increased activity (4- and 7-fold), as compared to the control group  
(Figures 5). The results confirm that compound 10c induced apoptosis in TNBC cells through 
the activation of caspase-3 in a time- and concentration-dependent manner (I). 
 
 
Figure 5. Effect of compound (10c) on the caspase-3 activity of MDA-MB-231 cells. (A) 
Cells treated for 24h (B) cells treated for 48h. *, and ***: p < 0.05, and p < 0.001, 
respectively, using one-way ANOVA followed by Dunnett's post-hoc test. 
 
4.3.4 Combination study of protoflavone derivatives    
 When comparing the effect of the hybrids to their fragments, compound 10a was 
found to be ca. 3.7 times more potent on MCF-7 cells, ca. 6.8 times more potent on MDA-
MB-231 cells, and ca. 5 times more potent on SiHa cells than compound 9. In contrast, it was 
ca. half as potent as compound 9 on the HeLa cells. It should be noted that compound 10a 
could directly be compared with compound 9, since the fragment coupled to 9, i.e. 11a itself 
did not exert any cytotoxic activity in the tested concentration range. 
However, in the case of compounds 10b-d, each fragment (9 and 11b-d) exhibited significant 
cytotoxic effects. Therefore, we performed a more sophisticated comparative evaluation to 
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quantitatively assess the added pharmacological benefit of linking the fragments into a hybrid 
molecule. In order to do this, we selected the Chou-Talalay method [108], which offers a 
well-established mathematical model for the calculation of drug-drug interactions, and two 
separate analyses were performed. The method was used in an unusual way that may be 
referred to as a “virtual combination study”. Treatment with the hybrid molecules 10b-d was 
considered as a 1:1 ratio combination treatment of their two relevant corresponding fragments 
(i.e., 9 and 11b for 10b, 9 and 11c for 10c, and 9 and 11d for 10d), and the cell viability data 
presented in Table 3 were re-evaluated accordingly by the CalcuSyn software. Further, a 
classical experimental combination study was also performed as a control, in which 
equimolar combinations of compounds 9 and 11b, 11c, or 11d were analyzed in comparison 
with the corresponding single treatments. The results of these calculations are presented in 
Figure 6. 
The virtual combination results clearly showed that the PrFl hybrid derivatives (10b-d) 
exerted stronger cytotoxic activities than their fragments alone, and the experimental 
combination showed that co-treatment with the fragments did not result in potent synergistic 
interactions. Therefore, it is clear that the activity increase is due to combining these 
fragments into hybrid molecules. 
The activity increase was particularly high in the case of MDA-MB-231 and SiHa cells, as 
shown by the strong and very strong synergistic interactions [108], respectively, in the virtual 
combination results (I). 
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Figure 6. Comparative analysis of the cytotoxic activity of the hybrid compounds 10b-d by 
the Chou-Talalay method with that of their fragments (9 and 11b-d). Results of a virtual 
(hybrid vs. fragments alone) and an experimental (Exp.: equimolar mixture of fragments vs. 
fragments alone) combination study are shown at 50%, 75%, and 90% of inhibition. CI: 
combination index; 0 < CI < 1, CI = 1, and CI > 1 represent synergism, additivity, and 
antagonism, respectively. Dm, m, and r represent the antilog of the x-intercept (activity), 
slope (shape of the dose-effect curve), and linear correlation coefficient (conformity of the 
data) of the median effect plot, respectively. CIavg = (CI50 + 2 × CI75 + 3 × CI90)/6. The lowest 
CIavg value demonstrates the highest added benefit of hybridization in terms of in vitro 
cytotoxic activity. 
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5 DISCUSSION 
 
5.1 Naringenin oxime derivatives 
5.1.1 Preparation of naringenin oximes and oxime ethers 
 Oximes or oxime ethers may have stronger antitumor activity than their 
corresponding oxo-compounds [95,97,98,111]. Therefore, we decided to synthesize such 
derivatives of NG, to possibly improve its anticancer activity. 
By using the procedure previously described by Türkkan et al. (2012) [90], two NG oxime 
isomers and five different oxime ether derivatives were obtained. 
The oxime derivatives of NG (2,3) were prepared from NG (1) by using hydroxylamine 
hydrochloride in the presence of potassium hydroxide and ethanol as solvent.  The reaction 
resulted in two geometric isomers E and Z, which only differ in the oxime configuration, and 
the isolated yields were 38 and 3%, respectively. The E isomer has previously been prepared 
by others, and its antimicrobial, antioxidant, antigenotoxic, and antiproliferative effects were 
reported [90–94]. The minor Z isomer was prepared by us for the first time.   
The five oxime ether derivatives (4–8) were analogously prepared from NG by applying the 
corresponding alkoxyamines, such as methoxy-, ethoxy-, tert-butoxy-, allyloxy-, and 
benzyloxyamine hydrochloride in pyridine, and the yields were 18, 52, 53, 58 and 5% 
respectively. In all these cases, only the formation of the E-oxime ether isomer was observed. 
The ethyl, tert-butyl and allyl ether derivatives were synthesized as new compounds, while 
the synthesis and characterization of the methyl and benzyl ether derivatives were  previously 
reported by Liu et al. (2013), and their cytotoxicity was also evaluated on human gastric 
cancer cell line SGC-7901 [98]. 
 
 
5.1.2 Antiproliferative effects of naringenin oximes and oxime ethers 
 Several in vitro studies demonstrated that NG could suppress cell proliferation, 
influence cell cycle suppression, and induce apoptosis on cancer cell lines of various origin, 
including human pancreatic, ovarian, breast, and uterine cancer, and leukemia [112–114]. 
The present study was carried out to analyze the pharmacological effect of the NGOX 
derivatives against different types of cancer cell lines with more emphasis on the 
gynecological cancer cell types. The cytotoxic activity of eight compounds including NG and 
its oximes and oxime ethers was tested in vitro against human gynecological cancer cells, 
including four adherent cell lines: cervical (SiHa, HeLa) and breast (MDA-MB-231, MCF-7). 
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Additionally,  the activity of the compounds was also tested on a human leukemia cell line 
(HL-60). First bioactivity screening was performed by MTT assay, which is based on the 
selective capacity of living cells to produce the mitochondrial enzymatic conversion of the 
yellow soluble salt of MTT to an insoluble purple precipitate of formazan crystals during a 
four-hour incubation period  [115]. IC50 values were determined only for those compounds 
that demonstrated growth inhibition of higher than 75% at a concentration of 50 µM. The 
results showed that naringenin t-butyl oxime derivative (6) exerted the strongest 
antiproliferative effect on the tested cancer cell lines. Other compounds, such as the E-oxime 
(2), methyl derivative (4), allyl-derivative (7), and benzyl-derivative (8) exerted moderate 
growth inhibition. 
In contrast, NG (1) and Z-oxime (3) did not present any antiproliferative activity on the 
examined cancer cell lines at any administered concentrations. At the same time, no marked 
cell line specificity was observed for the tested compounds. Our results were consistent with 
the related reports by Kocyigit et al. (2016) and Liu et al. (2013), suggesting that insertion of 
the oxime group to the structure of NG increased the cytotoxic activity of naringenin [92,98]. 
Furthermore, we proved for the first time that the elongation of the E-oxime ethers, and 
mainly if the ether is a t-butyl group at the carbonyl position in NG, results in a significant 
increase in the cytotoxic properties of the obtained compounds. Also, we observed that MCF-
7 and HeLa cancer cells appear to be more sensitive than SiHa and MDA-MB-231 cells. Our 
results are consistent with previous studies of other authors who explained that the 
modification of the flavanone carbonyl group at C-4 position with an oxime group created 
new derivatives with stronger anticancer activity against different types of cancer cell lines. 
Besides, a significant increase was observed in their cytotoxic activity when used to treat 
human colon adenocarcinoma HT-29, epidermoid carcinoma (KB), small cell lung cancer 
(NCI-H187), hepatocellular carcinoma HepD2 and Human breast cancer T47D [94,97,116]. 
On the other hand, many of the flavonoid compounds were found to inhibit the proliferation 
of HL-60 cells to some extent [117].  Our recent data revealed that NG and its oxime 
derivatives had impotent inhibitory effects against HL-60 human leukemia and cervical SiHa 
cells. This is also in agreement with an observation by Kocyigit et al. (2016), who previously 
reported that treatment of human peripheral blood mononuclear cells (PBMC) with high 
concentrations of 1280 µM and 640 µM of NG and NGOX, respectively, did not produce 
more than 60% inhibitory effects [92]. However, at the same time these findings conflict with 
Park et al. (2008), who reported that NG induced significant antiproliferative and apoptotic 
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effects in human leukemia THP-1 cells. These contradictory results may be due to the 
dependence of cytotoxic potency on the tested cell lines or to the higher concentrations in 
their study because they used 200-400 µM, while in our research the maximum concentration 
was 50µM [114]. Our results agree with the results of  Diaz et al. (2017) on the impacts of 
their synthesized flavone oxime ethers against MDA-MB-231 with a value of IC50  (28.7 
µM), which was close to the effects of our potent compound against the same cells [96]. 
 
5.1.2 Cell cycle analysis 
 Measurement of the DNA content by flow cytometric cell cycle analysis is considered 
an attractive approach and played an essential role in cancer research screening or studying 
the mechanism of action of anticancer agents [118]. The cytotoxic activity of Fls was 
qualified for their effects on cell cycle progression and triggering apoptosis [119]. Based on 
the antiproliferative effects, our results showed that a new derivatized NGOX ether has a 
potent activity. Furthermore, flow cytometric cell cycle analyses were performed to prove the 
in vitro mechanism of action. Gynecological cancer cell lines that were treated with prepared 
compounds elicited a considerable rise in the number of hypodiploid cells (subG1 population) 
only in HeLa and SiHa cells after a 24 h incubation period, which indicates that the cytotoxic 
activity of compound 6 in HeLa and SiHa cells occurs via apoptosis. In addition, it also 
brought about a disruption in the cell cycle in a concentration-dependent manner. Stronger 
effects were observed on HeLa cells, which were accompanied by preventing the cancer cells 
from entering the G1 phase, which was detected from the significant decrease in the 
proportion of the G1 stage and the corresponding increase in the S phase, while in SiHa cells 
these effects were just the contrary. Besides, our study found that the tested compound did 
not interfere with the cell distribution of MDA-MB-231 cancer cells, not even at the highest 
concentration. These data suggest that the effect of NGOX ether (6) on the cell cycle 
progression depended on the cancer cell type. An earlier report showed that when treating 
two human nasopharyngeal carcinoma cell lines with WTC-01, a synthetic oxime-containing 
flavone caused G2/M phase suppression and increased apoptosis in a time- and dose-
dependent manner [95]. This different cell cycle distribution may be dependent on cell lines 
and different tested types of flavonoid oxime. 
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5.1.3 Caspase-3 activity 
 Apoptosis, programmed cell death, is a highly regulated process that maintains an 
rquilibrium between cell proliferation and cell death. Hence, drugs that exhibit the ability to 
produce apoptosis and inhibit uncontrolled cell proliferation may be useful in managing and 
treating cancer disease. It was recorded that caspase-3 is a common effector enzyme that 
plays a principal role in the caspase-mediated apoptosis pathway, which can be detected by 
immunohistochemical, optical, and biochemical methods [120,121]. Khalilzadeh et al. (2018) 
described that caspase-3 has a vital role in both extrinsic and intrinsic pathways, and its 
detection is an essential tool for monitoring the competence of pharmaceuticals, chemo- and 
radiotherapy of cancers [122]. The antiproliferative and apoptosis activity of t-butyl 
derivative (6) was confirmed by measuring the proapoptotic property of caspase-3 level 
during 24 h on HeLa cells. The present study suggested that compound 6 induced apoptosis 
in a concentration-dependent manner, which was established by the significant increase in 
caspase-3 activity besides the considerable rise in the subG1 proportion. Our results 
confirmed that the t-butyl group added to NG significantly enhanced programmed cell death 
in HeLa cancer cells and thus could be considered as a promising agent that can be used for 
the treatment of cervical HeLa cancer cell lines. However, there is no available report 
demonstrating the caspase activity of this new oxime derivative compound on cancer cells. 
No previous scientific report has been published on the caspase activity of these oxime 
compounds against cancer cells; we were the first to investigate the caspase-3 effects of 
naringenin t-butyl oxime in the cancer cells. 
 
5.1.4 Antioxidant activity 
 The free radicals are responsible for the induction of oxidative damage that leads to 
diseases, including cancer. Hunyadi (2019) mentions that antioxidants’ secondary metabolites 
are able to decrease the oxidative stress through free radical scavenging or modulating the 
antioxidant and pro-oxidant enzymes [123]. This antioxidant activity fundamentally depends 
on the chemical structure of these compounds [124]. Therefore, the present research was 
carried out to evaluate the antioxidant activity of NG and their synthesized oxime derivatives 
by measuring oxygen radical absorbance capacity (ORAC), their ability to inhibit the 
xanthine oxidase (XO) activity, and scavenge diphenyl-2-picrylhydrazyl (DPPH) radical. Our 
results revealed that higher DPPH radical scavenging activity can only be observed in the 
case of E-oxime and oxime methyl ether and is still stronger than that of NG. Concerning the 
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DPPH scavenging activity here, our study was consistent and confirmed earlier findings 
according to which synthesized NGOX have an antioxidant capacity higher than their parent 
compounds [92]. Also, similarly to the study of Potaniec et al. (2014), it was observed that 
NGOX and flavanone oxime have stronger DPPH antioxidant properties than the 
corresponding substrates but comparable to ascorbic acid activity; they did not have any 
significant antioxidant effect [91]. Furthermore, we observed that E-oxime was an order of 
magnitude more potent in this respect than Z-oxime, these observations on the DPPH assay 
reveal that the scavenging activity of the prepared compound depends on the number and 
position of the hydroxyl (OH) group. 
On the other hand, in exception of the oxime methyl ether derivative, which registered the 
highest antioxidant properties in both the ORAC and the DPPH assays, and this activity was 
more elevated than the positive control rutin in the ORAC assay, the other additional 
substitution on the synthesized NGOX including t-butyl caused reduction in XO inhibition 
and ORAC activity as compared to NG. This finding suggests that replacement at position C4 
(C=O) of naringenin with oximes caused a reduction in antioxidant activity. Our results are in 
disagreement with Nile et al. (2018), who reported that flavonoid derivatives can be 
considered as potent antioxidants and XO inhibitors [61], and this difference in antioxidant 
effects might be due to various Fl derivatives.  Moreover, our results demonstrated that 
NGOX derivatives, despite their in vitro cytotoxic effects, did not show any apparent 
correlation to their antioxidant capacities. This suggests that the potential antitumor action of 
these compounds is not related to their antioxidant properties.  
 
5.2 Protoflavone derivatives 
 
5.2.1 Antiproliferative effects 
 
 The present results displayed that synthesized hybrid derivatives (10a-d) and their 
relevant fragments (9 and 11a-d) were able to suppress significantly the proliferation of 
human breast and cervical cancer cells in a concentration-dependent character. They showed 
stronger activity than cisplatin, a conventional chemotherapeutic drug in all tested cancer cell 
lines. As demonstrated, their relevant fragments (9 and 11b-d) have a significant cytotoxic 
effect, while in contrast, particle (11a) did not show any antiproliferative effects. 
Additionally, we also observed that MDA-MB-231, a TNBC and SiHa, an HPV 16+ cervical 
squamous cell carcinoma, were considered sensitive to the cytotoxic action of hybrid 
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compounds. In a previous in vitro study, it was reported that PrFl derivatives provoke 
cytotoxic effects on TNBC and cervical cancer cells in a concentration-dependent manner 
[125–127]. Our results are concordant with the findings reported by Lin et al. (2007), 
Hunyadi et al. (2011) and Lin et al. (2005), concluding that modification analogs of synthetic 
and isolated protoapigenone from Thelypteris torresiana have intense antiproliferative 
activity against breast cancer cells MDA-MB-231 and MCF-7 [99,128,129]; and also 
consistent with a study conducted by Chen et al. (2013), indicating that protoapigenone 
derivative (WYC02) caused a concentration-dependent cytotoxic effect against HeLa and 
SiHa cells [130]. 
Moreover, the cytotoxicity of the potent compounds (10b and 10c) was evaluated against 
non-cancerous mouse embryonic fibroblast cell lines (NIH/3T3) and it was found that both 
compounds exhibited less toxicity against these healthy cell lines. These data suggested that 
synthesized compounds have selective cytotoxicity on breast and cervical cancer cells. Fls 
can be considered as potential therapeutic agents due to their properties to kill tumor cells 
with less or no effect on healthy cells [131]. Our results are consistent with Yuan et al. 
(2012), indicating that protoapigenone analog (RY10-4) has potent cytotoxic effects on the 
MCF-7 and MDA-MB-231 cancer cells and offers satisfying selectivity for cancer cells with 
fewer cytotoxic effects against MCF-10A [132]. Also, they are in agreement with Danko et 
al. (2012), who found that methyl PrFl derivatives exhibited moderate selectivity toward 
MDR cancer cells [125].  
 In the present study, these data suggest that the antiproliferative activity of the newly tested 
hybrid PrFl derivatives was dependent on the position and nature of the fragment on the 
protoflavone-chalcone hybrids with triazole linker and showed that the presence of the 
methoxy group on the hybrid compound structure was the potent toxic effect.  
 
5.2.2 Cell cycle analysis 
 Cell cycle regulation and apoptosis are supposed to be essential strategies in the 
development of antitumor agents [133]. To study the mechanism of action of the synthesized 
PrFl derivatives, we performed cell cycle analyses, and measured caspase-3 activity, DNA 
damage, cell death induction, and mitochondrial function. We evaluated the cell cycle 
progression of two compounds 10b and 10c, which exhibit potent cytotoxic effect in cervical 
SiHa and TNBC cells. The present study in both tested cancer cells observed that both tested 
compounds increase the cell population in the subG1 phase. In the case of MDA-MB-231, the 
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effect was associated with a reduction in the percentage of G1 phase cells in a concentration-
dependent manner after 24h, which indicates a hallmark of enhanced apoptosis, with 
noticeable effects detected after exposure to compound 10c.  These results are consistent with 
a report conducted by Chen et al. (2011), who discovered that protoapigenone played a vital 
role in a concentration-dependent manner in inducing apoptosis by increasing the proportion 
of subG1 population in TNBC [127]. These results are in concord with those reported by 
Chang et al. (2008) and Chiu et al. (2009), who found that the treatment of human lung 
adenocarcinoma (H1299) and ovarian cancer cell lines (SKOV3 and MDAH-2774) with 
protoapigenone induced apoptosis and caused cell accumulation in the subG1 phase in a 
dose-dependent manner [134,135]. 
Moreover, Stankovic et al. (2015) demonstrated that 6-bromoprotoflavone derivative induced 
cell growth inhibition and decreased the level of the G1 phase of glioma MDR cancer cells 
[136]. Additionally, our results conflicted with Chen et al. (2013), who concluded that HeLa 
cells, when treated with WYC02, a synthetic protoapigenone derivative, caused cell cycle 
distribution and accumulation in the S and G2/M phases [130], while our tested compounds 
did not show any noticeable effects in these phases in both tested breast and cervical cancer 
cells. This may be due to the varied mechanisms of action of the various tested cancer cells 
and the different structure of the tested compounds.  
 
5.2.3 Caspase-3 and apoptotic activity 
 
 Most of the anticancer therapeutic strategies and drug development aim to promote 
apoptosis in cancer cells [120]. The induction of apoptosis is considered one of the most 
critical points in the promising therapeutics for cancer. In particular, caspase-3, which is a 
member of the cysteine-aspartic acid protease family, plays an essential role as a crucial 
executioner protein of apoptotic pathways [1,137]. The activation of both the death extrinsic 
receptor and the mitochondria intrinsic receptor pathways of apoptosis converge in the 
activation of caspase-3, and its activation is considered as a hallmark for response estimation 
to anticancer therapy. Our results demonstrated that among all the synthetic and fragment 
hybrid PrFl compounds, 10c was prominent in the cytotoxic and apoptotic effects through 
triggering caspase-3. 10c was found to be potent inducing caspase apoptosis in the TNCS in a 
concentration- and time-dependent manner. Our data suggest that cytotoxic indication 
mediated by the PrFl derivatives was due to apoptotic cell death, which is in agreement with 
the findings of Wang et al. (2017), who reported that any drugs directly activating caspase-3 
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are of interest as anticancer agents [138]. This is also consistent with Chen et al. (2011), who 
demonstrated that protoapigenone activated caspase-3 in TNBC [127]. Furthermore, the 
importance of caspase activation to cause apoptosis in the breast cancer cells was supported 
and confirmed by the cooperation study data. 
 
5.2.4 Combination study 
 
 ATM and ATR are attractive novel antitumor targets currently being investigated in 
several related clinical trials [139–141] . These two kinases are activated upon DNA damage 
induced by oxidative stress and they play an essential role in the regulation of DNA repair 
pathways [142]. Therefore, Hijova (2014) suggested that simultaneously targeting DDR and 
inducing oxidative stress may be a relevant antitumor strategy [143]. Protoflavones are 
efficient inhibitors of the ATR kinase, and, at the same time, they are also known to induce 
oxidative stress [110,127]. Chalcones may exert cytotoxic effect against cancer cell lines 
through various mechanisms of action, including the induction of oxidative stress and 
interfering with the mitochondrial membrane potential [144–146]. 
In our study, we explored the anticancer activities of a set of hybrid  molecules obtained from 
our collaboration partners (Prof. Antal Csámpai, Institute of Chemistry, Eötvös Loránd 
University, Budapest, Hungary). These compounds represent an example for fragment-based 
drug design, and they were obtained from a protoflavone and a chalcone fragment through 
click reaction forming a triazol linker. According to the above considerations, they were 
hypothesized to combine complementary pharmacological properties. 
When assessing the compounds’ cytotoxicity on our gynecological cancer cell line panel, we 
found strong activities with IC50 values in a couple of hundreds nanomolar concentration 
range. Even though these activities were clearly much more potent than that of the 
protoflavone fragment, we decided to perform a more sophisticated mathematical evaluation 
to elaborate the pharmacological benefit of the hybrid coupling as compared to the separate 
bioactivity of the individual fragments. This clearly showed that, considering the hybrids as 
1:1 ratio mixture combination treatment in a “virtual combination study”, a strong synergism 
can be calculated, and therefore ample pharmacological benefit of the coupling may 
reasonably be concluded. This mathematical evaluation also provides extra information 
concerning the bioactivity of a hybrid molecule vs. that of its corresponding hybrids as 
compared to a simple intuitive comparison of the IC50 values. For example, compound 10c 
was significantly more cytotoxic on MDA-MB-231 cells than 10b by means of the non-
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overlapping confidence intervals of their IC50 values. When comparing the virtual 
combination indices of these two hybrids, however, the opposite trend may be observed, i.e. a 
more pronounced activity increase was gained when compound 10b was formed from its 
fragments, as compared to the case of 10c. 
Using the Chou-Talalay method as a mathematical tool to perform a quantitative comparison 
between the bioactivity of two fragments and their corresponding hybrid is, to the best of our 
knowledge, a novel approach. We believe that with an appropriate selection of fragments to 
evaluate, such a virtual combination study provides a reasonable and easy-to-use platform to 
assess the bioactivity of hybrid compounds in general, therefore, we suggest an extension for 
the applicability of the Chou-Talalay method to analyze related bioactivity data. 
 
5.2.5  Collaboration findings  
 
 The hybrid compounds were further tested within an international collaboration 
network including Serbian (Dr. Milica Pešić, Institute for Biological Research, Department of 
Neurobiology, University of Belgrade, Belgrade, Serbia), Taiwanese (Prof. Hui-Chun Wang, 
Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan) 
and Turkish (Prof. Engin Ulukaya, Istinye University, Istanbul, Turkey) partners. Their 
findings provided independent confirmation of our results, and provided some mechanistical 
background to the observed potent antitumor activity of the hybrid compounds. For more 
details see the Reference (I). 
 The potential of hybrid compounds 10a-d to induce cell death in both tested breast 
cancer cell lines is shown in Figure 7.   
 
Figure 7. Cell death induction on the (A) MCF-7 and (B) MDA-MB-231 cells by the hybrid 
compounds (10a-d). After treatment with 500 nM of each compound for 72 h.  
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 The compounds were also tested for their capacity to inhibit DNA damage response 
through the ATR-dependent signaling pahtway. Further, their effect on the intracellular ROS 
and RNS production was also tested (Figure 8). 
 
Figure 8. Effects of compounds (10a-d) on DNA damage response and redox balance in 
breast cancer cells. (A) Effect on Chk1 phosphorylation in MCF-7 cells, PA 
(protoapigenone); (B) Effect on ROS production; (C) Decrease in ROS production by 10a; 
(D) Effect on RNS production; (E) Increase in RNS production by 10a. 
 
 As shown in Figure 8A, the treatment with all tested compounds 10a-d exhibited a 
significant suppression of cisplatin-induced Chk1-S345 phosphorylation and the activity was 
more potent than that of the positive control. Also, the hybrid compounds inhibited the DDR  
and were more potent than the ATR inhibitor fragment. Based on the pro-oxidant properties 
of both linked fragments, i.e., PrFl and chalcone, the intracellular ROS and RNS levels in the 
breast cancer cells were investigated after treatment with PrFl derivatives ( Figure 8B-E). 
  The integrity of mitochondrial membrane potential (MMP) after the treatment of both 
cancer cell lines with the hybrid compounds 10a-d was also tested (Figure 9).   
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Figure 9. Hybrid-protoflavones induce mitochondrial membrane depolarization. (A) Increase 
in the ratio of green to red fluorescence (FL1/FL2) assessed by JC-1 staining in MCF-7 and 
MDA-MB-231 cells after 24 h treatments with one µM of compounds 10a-d; (B) Illustration 
of the effect induced by 10b in MCF-7 cells; (C) Illustration of effects caused by 10b in 
MDA-MB-231 cells. 
 
 Our cooperator’s in vitro findings further demonstrated that the hybrid compounds 
exhibited the ability to induce cell death with late apoptosis in both breast cancer cells and 
accompanied by necrotic cell death in the MCF-7 cells.  
 They observed that all treatments with hybrid compounds induced significant late 
apoptosis in both cell lines, while a substantial increase in primary necrosis was present only 
in the MCF-7 cells. On the other hand, only 10c and 10d caused a substantial decrease in the 
cell viability of MDA-MB-231 cells during the incubation period of this bioassay. It is worth 
noting that MCF-7 cells responded differently to the treatment when compared with the 
MDA-MB-231 cells. Moreover, substantial primary necrosis was observed in the MCF-7 
cells. 
 Several ATR or checkpoint kinase inhibitors are currently being developed with an 
aim to selectively target tumors with or without a co-treatment with a DNA damaging 
chemotherapeutic agent [140,147]. Our current study showed that all hybrid compounds 10a-
d induced apoptotic cell death and DNA damage. These data support the previous results 
showing that protoapigenone and its derivatives caused  DNA damage and cell death 
induction in the breast, prostate, and lung cancer cells [127,134,148]. In this regard, Kuo et 
al. (2016) reported that dietary Fls could inhibit Chk1 phosphorylation and impair DNA 
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repair pathways to increase breast cancer sensitivity to cisplatin treatment [149]. Similarly, 
our results were consistent with Wang et al. (2012) observing that PrFl derivatives 
(WYC0209 and WYC02) decreased the cisplatin-induced Chk1 phosphorylation in MDA-
MB-231 breast cancer cells [110]. In view of these results in the current study, we suggest 
that effect on the DNA damage response plays an important role in the cytotoxicity of the 
hybrid compounds 10a-d. 
  Among all the tested compounds, only 10a and 10b  caused a significant decrease in 
ROS production in the MCF-7 cells, whereas TNBC did not show any noticeable effects. In 
respect to RNS levels, compounds 10c and 10d elicited a considerable increase in MCF-7 
cells. Furthermore, the most noticeable effect on RNS levels was observed with 10a, 
suggesting its significant pro-oxidant activity in MDA-MB-231 cells. On the other hand, 10d 
significantly reduced the RNS levels in TNBC cells. 
Numerous previous studies discussed that exposure of human glioma U87-TxR, breast MDA-
MB-231, and prostate DU145 cancer cells to protoapigenone and its analogs increased the 
levels of intracellular ROS production [127,136,148]. On the contrary, our results on the 
protoflavone-chalcone hybrids showed that these compounds can scavenge ROS and induce 
RNS production in both tested breast cancer cells. Similar opposite effects on the ROS and 
RNS production were previously observed with ferrocene–quinidine hybrids [29] containing 
the same triazole-linked ferrocene moiety as compound 10a [150].  
 While all the tested compounds 10a-c displayed potent mitochondrial membrane 
depolarisation in MDA-MB-231 and MCF-7 cancer cells, compound 10d showed 
pronounced selectivity towards MDA-MB-231 cells in this regard. Although this is just one 
aspect of a clear multitarget antitumor action of these compounds; it may still be worth noting 
that 10d showed the highest selectivity towards MDA-MB-231 versus MCF-7 among the 
hybrids in the cytotoxicity assay.  Further, it may be hypothesized that the induction of late 
apoptosis after 72 h treatment by 10d and other hybrid compounds (Figure 7) is due to 
proapoptotic factors released from affected mitochondria whose proton leakage was observed 
after 24 h treatments.  
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6 SUMMARY 
 
 The present PhD work aimed to contribute to the knowledge available on the 
antitumor properties of flavonoids through the in vitro evaluation of the bioactivity of some 
uncommon semi-synthetic derivatives against a panel of breast and cervical cancer cell lines 
that are well-established models for certain types of gynecological cancer. 
The work included the semi-synthetic preparation of seven naringenin oxime and oxime ether 
derivatives prior to their bioactivity testing, and the in vitro evaluation of nine protoflavone-
chalcone hybrid compounds and their reference fragments against breast (hormone-dependent 
MCF-7 and triple-negative MDA-MB-231), and cervical (SiHa & HeLa) cancer cell lines in 
addition to human HL-60 leukemia cells and non-cancerous mouse embryonic fibroblasts 
(NIH/3T3). The work included cytotoxicity, cell cycle distribution, caspase-3 activity, and 
antioxidant activity evaluations. Further, the cytotoxic activity of the hybrid compounds was 
evaluated in comparison with that of their corresponding fragments in a virtual and 
experimental combination study. 
In summary, our work led to the following results. 
 Two naringenin oxime isomers and five oxime ether derivatives were synthesized, 
purified and characterized. Four of these compounds, such as the minor product 
naringenin Z-oxime, and the ethyl, allyl, and tert-butyl ethers of naringenin E-oxime 
were prepared as new compounds. 
 When evaluating the in vitro cytotoxicity of the prepared derivatives of naringenin, 
tert-butyl oxime ether (6) showed the most potent effects on different gynecological 
cancer cells, with significant activity against MCF-7 and HeLa cells.  
 The flow cytometric analysis of compound (6) on gynecological cancer cells revealed 
significant accumulation of cells in the hypodiploid (subG1) phase in HeLa & SiHa 
cell lines, indicating the apoptosis induction effect, and induced cycle suppression at 
G2/M stage in MCF-7 cancer cells. Further, the proapoptotic activity of this 
compound was confirmed in HeLa cells by detecting the increased activity of 
caspase-3. 
 To our surprise, naringenin methyl oxime ether was more potent in the ORAC assay 
than its parent compound, while all other analogs were up to an order of magnitude 
less active. This suggests good peroxyl radical scavenging capacity for this 
compound.  
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 There was no apparent correlation between the in vitro cytotoxic and antioxidant 
activities of the tested compounds, suggesting that their anticancer effects are likely 
not related to their antioxidant properties.  
 Four protoflavone hybrid compounds were identified as promising antitumor lead 
compounds based on their prominent in vitro cytotoxic effects and their selectivity on 
different breast and cervical cancer cells with antiproliferative effects better than 
cisplatin. 
 The most potent compounds have an intense proapoptotic effect on TNBC, as 
evidenced by flow cytometric investigation and caspase-3 activity. It was shown that 
compound 10c induces a considerable expansion in caspase-3 activity in a 
concentration-time dependent manner with a significant increase in the sub G1 phase. 
 A novel approach was used to evaluate the bioactivity of the hybrid compounds in 
comparison with that of their corresponding fragments. A virtual combination study 
was performed by using the Chou-Talalay method as a mathematical tool, and results 
were compared to the corresponding experimental combinations of the cells with non-
coupled fragments. This gave valuable extra information as virtual combination index 
values and confirmed that the studied hybrid compounds are much more potent than 
what would be expected by a mathematical sum of the bioactivity of their fragments. 
 Based on the above, we demonstrated the use of a novel approach to evaluate the 
bioactivity of hybrid compounds in general, and suggested an extension of the 
applicability of the Chou-Talalay method, one of the currently available most popular 
platforms for drug-drug combination studies. 
Altogether, our present study provided valuable information about the antitumor potential of 
two series of unusual semi-synthetic flavonoid derivatives, and made a significant 
contribution to identifying a set of highly potent hybrid lead compounds obtained through 
fragment-based drug design. Further, by providing a novel use for an existing convenient and 
very widely used mathematical platform, we believe our study may have contributed to the 
research of hybrid compounds also in a more general manner. 
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